The specialist cancer drug discovery and development business has today announced that the discovery and biological characterisation of its lead candidate CHK1 inhibitor CCT245737 has been published in the peer-reviewed journal, Oncotarget. The paper describes how oral delivery of CCT245737 boosts the effectiveness of conventional chemotherapies and could be used to treat lung and pancreatic cancers. This is not the first time the science behind the programme being co-funded by Sareum and the ....